Quercus Molecular Design, LLC
Biotech · Private
antifungal antifolate molecules targeting dihydrofolate reductase (DHFR) for treating cryptococcal meningitis and disseminated fungal infections
- Grants
- $2.2M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Developing Multi-targeting Antiviral Agents Against Herpes Simplex 1 | $308,940 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing Multi-targeting Antiviral Agents Against Herpes Simplex 1 | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Antimetabolites for Acute Myeloid Leukemias | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Broad Spectrum Antifungal Agents | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · New Agents for the Treatment on Mycobacteria Avium Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Agents Targeting Cryptococcal Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · New Agents for the Treatment on Mycobacteria Avium Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Agents Targeting Cryptococcal Infections | $297,725 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3223 | VELUM INC | — | — |
| 3224 | Proneurogen, Inc | — | — |
| 3225 | CLARADELE PHARMACEUTICALS, INCORPORATED | — | — |
| 3226 | Quercus Molecular Design, LLC | — | — |
| 3227 | CELLGORTHMICS, INC | — | — |
| 3228 | ROCKLAND IMMUNOCHEMICALS, INC. | — | — |
| 3229 | GATACA, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.